Keywordshuman herpesvirus 8; hepatitis C virus; drug user; prevalence; China; KSHV; vIL-6; vFLIP; NF-κB; Kaposi sarcoma; primary effusion lymphoma; multicentric Castleman disease; inflammation; tumor angiogenesis; KSHV; miRNA; lytic reactivation; latency; KSHV; HHV-8; receptors; integrins; signal induction; mode of entry; viruses; long non-coding RNA; epigenetics; viral latency; viral reactivation; KSHV; HHV-8; epidemiology; transmission; Kaposi’s sarcoma-associated herpesvirus (KSHV); gammaherpesvirus; long noncoding RNA; PAN; histone modification; chromatin; epigenetics; gene expression; KSHV; Kaposi’s sarcoma; AIDS; virus discovery; history; viral oncogenesis; KSHV; antiviral; nucleoside analog; DNA polymerase inhibitors; lytic cycle; ganciclovir; cidofovir; foscarnet; Kaposi’s sarcoma-associated herpesvirus (KSHV); genotyping; K1 gene; Xinjiang; Kaposi’s sarcoma-associated herpesvirus; KSHV; KS; minichromosome; DNA replication; reactivation; signaling; Kaposi’s sarcoma-associated Herpesvirus; Human herpesvirus-8; herpesvirus; reactivation; Rta; transcriptional activation; Pin1; Peptidyl-prolyl cis/trans isomerase; KSHV; reactivation; Lytic DNA replication; hypoxia; RTA; LANA; KSHV; ORF59; ORF57; RNA accumulation; RNA export; RBM15; KSHV; ORF57 protein; viral expression; posttranscriptional regulator; RNA processing; KSHV; vGPCR; Glycosylation
